Increased PT and Increased PTT
Coumadin therapy in the therapeutic or supratherapeutic range
Moderate to severe vitamin K deficiency
Treatment with high doses of heparin or low molecular weight heparin
Treatment with direct thrombin inhibitors, such as hirudin or related compounds (i.e., lepirudin, refludan) or argatroban
Moderate to severe DIC
Moderate to severe liver disease
A lupus inhibitor with an associated decrease in factor II or a lupus inhibitor strong enough to increase PT, as well as PTT
Suggested Additional Lab Testing
To assess the possibility of DIC, get D-dimer levels.
If D-dimers are elevated, measure platelet count and fibrinogen level.
Test for factors II, V, VII, and X to assess a PT prolongation.
Test for factors VIII, IX, XI, and XII to assess a PTT prolongation.
In liver disease, all the factors can be low, except factor VIII, which tends to become elevated because it can be synthesized outside the liver.
Obtain liver function tests, especially serum albumin, to determine if the PT and PTT abnormalities could be associated with decreased production of coagulation factors by the liver.
Get a value for PTT after the sample is treated with an enzyme that degrades heparin.
If PTT and PT normalize after removal of heparin from the sample, PT and PTT elevations are most likely associated with heparin or low molecular weight heparin treatment.
Do a lupus inhibitor test if there is no explanation for the PT and PTT prolongations from the previously mentioned tests.
Factor II level may be useful to accompany the lupus anticoagulant test, because some lupus anticoagulant patients have a low factor II, leading to a prolonged PT.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Next Article in LabMed
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Patent Foramen Ovale Closure for Stroke Prevention: Key Principles for Clinical Practice
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- FDA Grants Orphan Drug Status to Angelman Syndrome Treatment
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Clinical, Radiologic Markers Predictive of Cortical Superficial Siderosis in ICH Identified
- Migraine Pain Location May Not Have Clinical Implications